Trial Profile
A randomized, open-label, multi-center Phase II trial of bevacizumab and radiotherapy followed by bevacizumab and irinotecan vs. temozolomide and radiotherapy followed by temozolomide monotherapie in patients with newly diagnosed glioblastoma and a non-methylated MGMT-promoter (GLARIUS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Irinotecan (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms GLARIUS
- Sponsors Roche
- 01 Aug 2018 Results (n=142) published in the Journal of Cancer Research and Clinical Oncology
- 14 Mar 2016 Results published in the Journal of Clinical Oncology
- 13 Oct 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.